Risk of second primary cancer in patients with B-cell non-hodgkin lymphoma receiving rituximab-containing chemotherapy: A nationwide population-based study

Anticancer Research

Volumn 35, Issue 3, 2015, Pages 1809-1814

  Cho, Shih Feng ^a,b   Wu, Wan Hsuan ^c,d   Yang, Yi Hsin ^b   Chang, Chao Sung ^c,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c E DA HOSPITAL   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

Author keywords

Non Hodgkin lymphoma; Rituximab; Second primary cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; AGED; LYMPHOMA, B-CELL; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RISK; STATISTICAL MODEL;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; LOGISTIC MODELS; LYMPHOMA, B-CELL; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RISK;

EID: 84924943707     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Katanoda K and Yako-Suketomo H: Comparison of time trends in Hodgkin and non-Hodgkin lymphoma incidence (1973-97) in East Asia, Europe and USA, from cancer incidence in five continents Vol. IV-VIII. Jpn J Clin Oncol 38: 391-393, 2008.
2. Adamson P, Bray F, Costantini AS, Tao MH, Weiderpass E and Roman E: Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 43: 391-401, 2007.
3. Clarke CA and Glaser SL: Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94: 2015-2023, 2002.
4. Groves FD, Linet MS, Travis LB and Devesa SS: Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 92: 1240-1251, 2000.
5. Shan D, Ledbetter JA and Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652, 1998.
6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P and Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.
7. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A and Smith P: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417-1423, 2005.
8. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R and Unterhalt M: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725-3732, 2005.
9. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M and MabThera International Trial G: CHOP-like chemotherapy plus rituximab versus CHOPlike chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379-391, 2006.
10. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C and Tilly H: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116: 2040-2045, 2010.
11. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K and Barista I: Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48: 1307-1312, 2007.
12. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS and Chan PK: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27: 605-611, 2009.
13. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF and Kuo CY: Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22: 1170-1180, 2011.
14. Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P, Tucker MA, Fraumeni JF and Boice JD: Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85: 1932-1937, 1993.
15. Okines A, Thomson CS, Radstone CR, Horsman JM and Hancock BW: Second primary malignancies after treatment for malignant lymphoma. Br J Cancer 93: 418-424, 2005.
16. Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ and Linch DC: Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 24: 1568-1574, 2006.
17. Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383, 1987.
18. Deyo RA, Cherkin DC and Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613-619, 1992.
19. van der Kolk LE, Baars JW, Prins MH and van Oers MH: Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100: 2257-2259, 2002.
20. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F and Tedder TF: Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203: 743-753, 2006.
21. Glennie MJ, French RR, Cragg MS and Taylor RP: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837, 2007.
22. Pescovitz MD: Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6: 859-866, 2006.
23. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D and Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
24. Inoue S, Leitner WW, Golding B and Scott D: Inhibitory effects of B cells on antitumor immunity. Cancer Res 66: 7741-7747, 2006.
25. Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, Kaiser LR and Albelda SM: B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 31: 446-457, 2008.